Innovative Diagnostics PetDx's flagship product, OncoK9, offers a cutting-edge multi-cancer early detection blood test for dogs, providing a unique selling point for veterinary clinics seeking advanced diagnostic solutions.

Strategic Partnerships Partnered with Petco to offer OncoK9 screenings in their clinics, PetDx is expanding its market reach and creating opportunities to target a broader pet owner base across various veterinary channels.

Funding & Growth With a recent $62 million Series B funding round and significant institutional backing, PetDx is positioned for rapid scaling and market penetration within the pet diagnostics industry.

Market Focus Operating in the growing biotech sector focused on pet health, PetDx presents an opportunity to tap into the increasing demand for innovative veterinary diagnostics and genomics-based solutions.

Tech-Driven Approach Utilizing advanced technologies such as next-generation sequencing and proprietary bioinformatics, PetDx emphasizes its capability to deliver reliable, early cancer detection, appealing to veterinary practices invested in cutting-edge care.